Relationship of olfactory function with olfactory bulbus volume, disease duration and Unified Parkinson’s disease rating scale scores in patients with early stage of idiopathic Parkinson’s disease

Hakyemez, Hüsniye Aylin; Veyseller, Bayram; Özer, Feriha; Özben, Serkan; Bayraktar, Gülüm Ivgin; Gürbüz, Defne; Cetin, Sibel; Yıldırım, Yavuz Selim

doi:10.1016/j.jocn.2012.11.017

Cited by 24 publications

(25 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to this study, olfactory testing can successfully distinguish PD patients from Non-parkinsonism, which is in line with previous studies [22][23][24][25]. However, olfactory testing fails in distinguishing PD from APS or APS from Non-parkinsonism.…”

Section: Olfactionsupporting

confidence: 91%

The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes

et al. 2015

View full text Add to dashboard Cite

The aim of the study was to compare the efficacy of olfactory testing and presynaptic dopamine imaging in diagnosing Parkinsons disease (PD) and atypical parkinsonian syndromes (APS); to evaluate if the combination of these two diagnostic tools can improve their diagnostic value. A prospective investigation of 24 PD patients, 16 APS patients and 15 patients with non-parkinsonian syndromes was performed during an 18-month period. Single photon emission computed tomography with the presynaptic radioligand I-123-FP-CIT (DaTSCAN (R)) and olfactory testing with the Brief 12-item Smell Identification Test (B-SIT) were performed in all patients. DaTSCAN was analysed semi-quantitatively, by calculating two different striatal uptake ratios, and visually according to a predefined ranking scale. B-SIT score was significantly lower for PD patients, but not significantly different between APS and non-parkinsonism. The visual assessment of DaTSCAN had higher sensitivity, specificity and diagnostic accuracy compared to olfactory testing. Most PD patients (75 %) had visually predominant dopamine depletion in putamen, while most APS patients (56 %) had visually severe dopamine depletion both in putamen and in caudate nucleus. The combination of DaTSCAN and B-SIT led to a higher rate of correctly classified patients. Olfactory testing can distinguish PD from non-parkinsonism, but not PD from APS or APS from non-parkinsonism. DaTSCAN is more efficient than olfactory testing and can be valuable in differentiating PD from APS. However, combining olfactory testing and DaTSCAN imaging has a higher predictive value than these two methods separately.

Funding Agencies|Ostergotland County Council (ALF); Swedish Parkinsons Foundation

show abstract

Section: Olfactionsupporting

confidence: 91%

The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes

et al. 2015

View full text Add to dashboard Cite

Funding Agencies|Ostergotland County Council (ALF); Swedish Parkinsons Foundation

show abstract

“…However, we did not find any associations between anosmia and constipation, as indicated previously . This might be explained by the fact that anosmia also correlated with the duration of the disease and our patients had an average disease duration of only 6 months. The progression of the disease also has an effect on constipation, with patients with advanced disease showing higher prevalence of constipation .…”

Section: Discussionmentioning

confidence: 99%

Constipation is not associated with dopamine transporter pathology in early drug‐naïve patients with Parkinson's disease

Pagano

Yousaf

Wilson

et al. 2017

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…Motor assessment conditions are an important methodological aspect that has been somewhat neglected by the literature, which may partially explain the variability of findings [ 2 , 5 , 12 , 14 , 17 – 20 , 25 ]. Unlike most studies on the topic, in our cohort, motor symptoms (i.e., Hoehn and Yahr and UPDRS-III) were consistently evaluated in “off” state (i.e., overnight without antiparkinsonian mediation) to reduce the confounding effect of motor fluctuations.…”

Section: Discussionmentioning

confidence: 99%

“…Hyposmia in PD has been thought to be largely independent of disease duration, severity of motor symptoms, and current medication [ 3 – 5 , 11 – 20 ]. However, small associations with disease duration and/or disease severity have been reported [ 21 – 26 ].…”

Section: Introductionmentioning

confidence: 99%

Abnormal Olfaction in Parkinson’s Disease Is Related to Faster Disease Progression

Cavaco

Gonçalves

Mendes

et al. 2015

Behavioural Neurology

View full text Add to dashboard Cite

Introduction. A possible association between olfactory dysfunction and Parkinson's disease (PD) severity has been a topic of contention for the past 40 years. Conflicting reports may be partially explained by procedural differences in olfactory assessment and motor symptom evaluation. Methods. One hundred and sixty-six nondemented PD patients performed the Brief-Smell Identification Test and test scores below the estimated 20th percentile as a function of sex, age, and education (i.e., 80% specificity) were considered demographically abnormal. Patients underwent motor examination after 12 h without antiparkinsonian medication. Results. Eighty-two percent of PD patients had abnormal olfaction. Abnormal performance on the Brief-Smell Identification Test was associated with higher disease severity (i.e., Hoehn and Yahr, Unified Parkinson's Disease Rating Scale-III, Freezing of Gait questionnaire, and levodopa equivalent dose), even when disease duration was taken into account. Conclusions. Abnormal olfaction in PD is associated with increased severity and faster disease progression.

show abstract

Relationship of olfactory function with olfactory bulbus volume, disease duration and Unified Parkinson’s disease rating scale scores in patients with early stage of idiopathic Parkinson’s disease

Cited by 24 publications

References 6 publications

The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes

The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes

Constipation is not associated with dopamine transporter pathology in early drug‐naïve patients with Parkinson's disease

Abnormal Olfaction in Parkinson’s Disease Is Related to Faster Disease Progression

Contact Info

Product

Resources

About